Trusted Resources: News & Meetings
Latest announcements and gatherings
Europe Grants Orphan Drug Status to JR-441, ERT for Sanfilippo A
The European Commission has granted an orphan drug designation to JR-441, JCR Pharmaceuticals’ brain-penetrating experimental enzyme replacement therapy (ERT) for Sanfilippo syndrome type A, the company has announced. The designation is given to investigative therapies with the potential to be safe and effective for rare, life-threatening, or chronically debilitating conditions that have no approved treatments, or where the potential therapy is showing significant benefit over existing treatments.
It is meant to accelerate JR-441’s clinical development and review by providing regulatory support and financial benefits. It also provides a 10-year marketing exclusivity period in Europe upon regulatory approval, if granted. JCR is planning to launch a global clinical trial testing the therapy in the first half of 2023. Sanfilippo syndrome type A, also known as mucopolysaccharidosis type IIIA, is caused by the absence or reduced activity of the heparan N-sulfatase enzyme due to mutations in the SGSH gene.
BookmarkRelated Content
-
The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: “The Example of Meta-A...Nonrandomized studies are usually exclud...
-
EMA Grants Orphan Drug Designation to JR-171 for the Treatment of Mucopolysaccaridosis Type I (MPS I)JCR Pharmaceuticals Co., Ltd. announced ...
-
Developing a Treatment Plan for Sanfilippo SyndromeSanfilippo syndrome is a neurodegenerati...
-
MPS 1: Where Are We NowDr. Sandra Kingma from the Centre for Ra...
-
Progression of Cardiovascular Manifestations in Adults and Children With Mucopolysaccharidoses With and Without Enzy...Cardiovascular involvement is among the ...
-
Gene Therapy for MPShttps://www.youtube.com/watch?v=Dh5pFgZd...
-
Gene Therapy for Neuronopathic Mucopolysaccharidoses: State of the ArtThe need for long-lasting and transforma...
Powered by
